CRM197

CRM197

CRM197 is a non-toxic mutant of diphtheria toxin that is used in various medical and research applications, particularly as a carrier protein in conjugate vaccines. It is a genetically modified form of the diphtheria toxin, where a single amino acid substitution (glycine to glutamic acid at position 52) renders it non-toxic.

Structure and Function

CRM197 is structurally similar to the native diphtheria toxin, but the mutation in its active site prevents it from inhibiting protein synthesis in cells, which is the mechanism by which the diphtheria toxin exerts its toxic effects. Despite this, CRM197 retains the ability to bind to the heparin-binding epidermal growth factor-like growth factor (HB-EGF) receptor, which is the same receptor used by the diphtheria toxin to enter cells.

Applications

CRM197 is widely used as a carrier protein in conjugate vaccines. Conjugate vaccines are designed to improve the immunogenicity of polysaccharide antigens, which are typically poorly immunogenic on their own. By conjugating these polysaccharides to a protein carrier like CRM197, the immune system is better able to recognize and respond to the antigen.

Some of the vaccines that utilize CRM197 as a carrier protein include:

• Pneumococcal conjugate vaccine
• Haemophilus influenzae type b (Hib) vaccine
• Meningococcal conjugate vaccine

Research and Development

CRM197 is also used in research settings to study receptor-mediated endocytosis and to investigate the mechanisms of toxin entry into cells. Its ability to bind to the HB-EGF receptor without causing toxicity makes it a valuable tool for studying cellular processes.

Safety and Efficacy

CRM197 is considered safe for use in humans, as it lacks the toxic activity of the native diphtheria toxin. Its use in vaccines has been associated with a strong immune response and has contributed to the effectiveness of several important vaccines.

History

The development of CRM197 as a non-toxic variant of diphtheria toxin was a significant advancement in vaccine technology. It was first described in the 1970s and has since become a standard component in many conjugate vaccines.

Also see

• Diphtheria toxin
• Conjugate vaccine
• Vaccine adjuvant
• Protein engineering

   This article is a  stub. You can help WikiMD by expanding it!

   This article is a immunology stub. You can help WikiMD by expanding it!